The American Journal of Medicine
Volume 121, Issue 1 , Pages 50-57, January 2008

Biomarkers to Predict Recurrent Cardiovascular Disease: The Heart and Soul Study

  • Michael G. Shlipak, MD, MPH

      Affiliations

    • Section of General Internal Medicine, San Francisco VA Medical Center, San Francisco, Calif
    • Department of Medicine, University of California San Francisco, San Francisco, Calif
    • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, Calif
    • Dr. Shlipak was funded by R01 DK066488.
    • Corresponding Author InformationRequests for reprints should be addressed to Michael G. Shlipak, MD, MPH, 4150 Clement Street (111A1), San Francisco, CA 94121.
  • ,
  • Joachim H. Ix, MD

      Affiliations

    • Division of Nephrology, University of California San Diego, Calif
  • ,
  • Kirsten Bibbins-Domingo, PhD, MD

      Affiliations

    • Division of General Internal Medicine, San Francisco General Hospital, San Francisco, Calif.
  • ,
  • Feng Lin, MS

      Affiliations

    • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, Calif
  • ,
  • Mary A. Whooley, MD

      Affiliations

    • Section of General Internal Medicine, San Francisco VA Medical Center, San Francisco, Calif
    • Department of Medicine, University of California San Francisco, San Francisco, Calif
    • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, Calif

Abstract 

Purpose

The study purpose was to evaluate the ability of 6 biomarkers to improve the prediction of cardiovascular events among persons with established coronary artery disease.

Background

Cardiovascular risk algorithms are designed to predict the initial onset of coronary artery disease but are less effective in persons with preexisting coronary artery disease.

Methods

We examined the association of N-terminal prohormone brain natriuretic peptide (Nt-proBNP), cystatin C, albuminuria, C-reactive protein (CRP), interleukin-6, and fibrinogen with cardiovascular events in 979 Heart and Soul Study participants with coronary artery disease after adjusting for demographic, lifestyle, and behavior variables; cardiovascular risk factors; cardiovascular disease severity; medication use; and left ventricular ejection fraction. The outcome was a composite of stroke, myocardial infarction, and coronary heart disease death during an average of 3.5 years of follow-up.

Results

During follow-up, 142 participants (15%) developed cardiovascular events. The highest quartiles (vs lower 3 quartiles) of 5 biomarkers were individually associated with cardiovascular risk after multivariate analysis: Nt-proBNP hazard ratio (HR)=2.13 (95% confidence interval [CI], 1.43-3.18); cystatin C HR=1.72 (95% CI, 1.10-2.70); albuminuria HR=1.71 (95% CI, 1.15-2.54); CRP HR=2.00 (95% CI, 1.40-2.85); and interleukin-6 HR=1.76 (95% CI, 1.22-2.53). When all biomarkers were included in the multivariable analysis, only Nt-proBNP, albuminuria, and CRP remained significant predictors of events: HR=1.88 (95% CI, 1.23-2.85), HR=1.63 (95% CI, 1.09-2.43), and HR=1.82 (95% CI, 1.24-2.67), respectively. The area under the receiver operator curve for clinical predictors alone was 0.73 (95% CI, 0.68-0.78); adding Nt-proBNP, albuminuria, and CRP significantly increased the area under the receiver operator curve to 0.77 (95% CI, 0.73-0.82, P<.005).

Conclusion

Among persons with prevalent coronary artery disease, biomarkers reflecting hemodynamic stress, kidney damage, and inflammation added significant risk discrimination for cardiovascular events.

Keywords: Albuminuria, Biomarkers, Cardiovascular events, Coronary artery disease, C-reactive protein, Cystatin C, Fibrinogen, Interleukin-6, N-terminal prohormone brain natriuretic peptide

 

 The Heart and Soul Study was supported by grants from the Department of Veterans Affairs, the Robert Wood Johnson Foundation, the American Federation for Aging Research, the Ischemia Research and Education Foundation, and the Nancy Kirwan Heart Research Fund. Dade Behring, Inc, paid for the cystatin C measurements. Roche Diagnostics paid for the Nt-proBNP assays.

PII: S0002-9343(07)00844-3

doi:10.1016/j.amjmed.2007.06.030

The American Journal of Medicine
Volume 121, Issue 1 , Pages 50-57, January 2008